Olga R. Magamedova
Olga R. Magamedova has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Polina S. Feoktistova
Loginov Moscow Clinical Scientific Center
2 shared publications - Arina A. Datsiuk
ГАУЗ НО "НИИКО "НОКОД
1 shared publication - Denis Sergeevich Fedorinov
Federal State Budgetary Research Institution «Russian Research Center of Surgery Named After Academician B.V. Petrovsky», Moscow 119991, Russia
1 shared publication - Egor P. Fekhtel
Moscow State Budgetary Healthcare Institution "Moscow City Hospital named after S.S. Yudin, Moscow Healthcare Department
1 shared publication - Ekaterina A. Mgar'
City clinical oncological dispensary
1 shared publication - Elena V. Glazkova
Moscow Multidisciplinary Clinical Center "Kommunarka
1 shared publication
Latest Publications
- Open Access
- 8 April 2026
- Published by Consilium Medicum in Journal of Modern Oncology
- Vol. 28 (1) , 37-45
Comparison of the efficacy of regorafenib and reintroduction of a combination of chemotherapy with anti-EGFR antibody in the third-line treatment of metastatic colorectal cancer with wild-type RAS and BRAF genes of left-sided localization – Results of a multicenter study of real-world practice
Aim. To compare the efficacy and toxicity of regorafenib therapy and the repeated use of anti-EGFR monoclonal antibodies (mAb) combined with chemotherapy (CT) in the third-line treatment of patients with left-sided metastatic colorectal cancer (mCRC) with wild-type RAS and BRAF genes who received anti-EGFR targeted therapy in the first line of treatment. Materials and methods. The database of patients with mCRC from 5 clinics in the Russian Federation was retrospectively analyzed. The study had 3 arms depending on the third-line therapy: regorafenib, reintroduction and rechallenge with the combination of CT and anti-EGFR mAb. In this paper, we present data comparing reintroduction and regorafenib therapy. Results. 132 patients with morphologically confirmed left-sided mCRC with wild-type RAS and BRAF genes who received at least 3 lines of drug therapy from 2014 to 2023 were identified: the first-line therapy included anti-EGFR mAb; 61 patients were reintroduced with a combination of CT with anti-EGFR mAb, and 71 patients received regorafenib in the third-line therapy. Disease control in the reintroduction group was achieved in 43 (70.5%) patients, compared with 18 (25.5%) in the regorafenib group (p = 0.0001). The six-month overall survival (OS) was 76% in the reintroduction group and 55% in the regorafenib group. The median OS in the reintroduction group was 18 months (95% confidence interval [CI] 11.9-24.0 months) and 10 months in the regorafenib group (95% CI 5.3-14.6 months; p = 0.05 according to the log-rank test; p = 0.013 according to the Breslow-Wilcoxon test; p = 0.024 according to the Tarone-Ware test; risk ratio 1.1, 95% CI 0.886-1.408; p = 0.349). Progression-free survival (PFS) was higher in the CT reintroduction group with anti-EGFR mAb (6 months [95% CI 5.3-6.6 months] than in the regorafenib group (3 months [95% CI 2.2-3.7 months]; p = 0.0001 according to the log-rank test, risk ratio 1.23, 95% CI 0.997-1.529; p = 0.053). We found no difference in the incidence of all-grade adverse events between the study groups (p = 0.19), nor in the incidence of grade 3-4 adverse events (p = 0.781). Conclusion. Compared with regorafenib therapy, re-administration of a combination of CT with anti-EGFR targeted therapy in the third-line treatment of patients with left-sided mCRC with wild-type RAS and BRAF genes was associated with a higher rate of disease control and better PFS and 6-month OS.
- 8 April 2026
- Published by Consilium Medicum in Journal of Modern Oncology
- Vol. 28 (1) , 37-45
Open AccessComparison of the efficacy of regorafenib and reintroduction of a combination of chemotherapy with anti-EGFR antibody in the third-line treatment of metastatic colorectal cancer with wild-type RAS and BRAF genes of left-sided localization – Results of a multicenter study of real-world practice
Aim. To compare the efficacy and toxicity of regorafenib therapy and the repeated use of anti-EGFR monoclonal antibodies (mAb) combined with chemotherapy (CT) in the third-line treatment of patients with left-sided metastatic colorectal cancer (mCRC) with wild-type RAS and BRAF genes who received anti-EGFR targeted therapy in the first line of treatment. Materials and methods. The database of patients with mCRC from 5 clinics in the Russian Federation was retrospectively analyzed. The study had 3 arms depending on the third-line therapy: regorafenib, reintroduction and rechallenge with the combination of CT and anti-EGFR mAb. In this paper, we present data comparing reintroduction and regorafenib therapy. Results. 132 patients with morphologically confirmed left-sided mCRC with wild-type RAS and BRAF genes who received at least 3 lines of drug therapy from 2014 to 2023 were identified: the first-line therapy included anti-EGFR mAb; 61 patients were reintroduced with a combination of CT with anti-EGFR mAb, and 71 patients received regorafenib in the third-line therapy. Disease control in the reintroduction group was achieved in 43 (70.5%) patients, compared with 18 (25.5%) in the regorafenib group (p = 0.0001). The six-month overall survival (OS) was 76% in the reintroduction group and 55% in the regorafenib group. The median OS in the reintroduction group was 18 months (95% confidence interval [CI] 11.9-24.0 months) and 10 months in the regorafenib group (95% CI 5.3-14.6 months; p = 0.05 according to the log-rank test; p = 0.013 according to the Breslow-Wilcoxon test; p = 0.024 according to the Tarone-Ware test; risk ratio 1.1, 95% CI 0.886-1.408; p = 0.349). Progression-free survival (PFS) was higher in the CT reintroduction group with anti-EGFR mAb (6 months [95% CI 5.3-6.6 months] than in the regorafenib group (3 months [95% CI 2.2-3.7 months]; p = 0.0001 according to the log-rank test, risk ratio 1.23, 95% CI 0.997-1.529; p = 0.053). We found no difference in the incidence of all-grade adverse events between the study groups (p = 0.19), nor in the incidence of grade 3-4 adverse events (p = 0.781). Conclusion. Compared with regorafenib therapy, re-administration of a combination of CT with anti-EGFR targeted therapy in the third-line treatment of patients with left-sided mCRC with wild-type RAS and BRAF genes was associated with a higher rate of disease control and better PFS and 6-month OS.
- Open Access
- 5 March 2024
- Published by Consilium Medicum in Journal of Modern Oncology
- Vol. 26 (1) , 118-121
EDP chemotherapy combined with somatostatin analogues and mitotane in the treatment of disseminated adrenocortical carcinoma: a clinical case
Adrenocortical carcinoma is an orphan disease with an annual incidence of 1–2 cases per 1 million adults. The median overall survival (OS) is only 17 months. Definitive surgery increases the median OS to 28 months. The article presents a clinical case of a patient with hormonally active adrenocortical carcinoma of the right adrenal gland, accompanied by tumor thrombosis of the inferior vena cava extending to the right atrium. Surgery was performed for the thrombus removal. A wrong initial diagnosis led to a delay in adjuvant mitotane therapy. The recurrence of the disease was treated with mitotane and somatostatin analogues, considering the high expression of somatostatin receptors in the tumor. At the second progression, the patient was switched to chemotherapy in the EDP regimen combined with continued therapy with mitotane and octreotide, resulting in long-term control of the disease. The time without progression and OS were 18 and 42 months, respectively.
- 5 March 2024
- Published by Consilium Medicum in Journal of Modern Oncology
- Vol. 26 (1) , 118-121
Open AccessEDP chemotherapy combined with somatostatin analogues and mitotane in the treatment of disseminated adrenocortical carcinoma: a clinical case
Adrenocortical carcinoma is an orphan disease with an annual incidence of 1–2 cases per 1 million adults. The median overall survival (OS) is only 17 months. Definitive surgery increases the median OS to 28 months. The article presents a clinical case of a patient with hormonally active adrenocortical carcinoma of the right adrenal gland, accompanied by tumor thrombosis of the inferior vena cava extending to the right atrium. Surgery was performed for the thrombus removal. A wrong initial diagnosis led to a delay in adjuvant mitotane therapy. The recurrence of the disease was treated with mitotane and somatostatin analogues, considering the high expression of somatostatin receptors in the tumor. At the second progression, the patient was switched to chemotherapy in the EDP regimen combined with continued therapy with mitotane and octreotide, resulting in long-term control of the disease. The time without progression and OS were 18 and 42 months, respectively.